GeneDx Holdings Corp. Interest Income (Expense), Net
GeneDx Holdings Corp. (WGS) reported Interest Income (Expense), Net of -$597.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-29.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2024-04-29
- GeneDx Holdings Corp. interest income (expense), net for the quarter ending 2024-03-31 was -$597.00K.
- GeneDx Holdings Corp. interest income (expense), net for the quarter ending 2023-12-31 was -$978.00K, a 393.69% decline year-over-year.
- GeneDx Holdings Corp. interest income (expense), net for the quarter ending 2023-09-30 was $1.05M, a 454.21% increase year-over-year.
- GeneDx Holdings Corp. interest income (expense), net for the quarter ending 2023-06-30 was $1.07M.
- GeneDx Holdings Corp. interest income (expense), net for fiscal 2023 was $1.11M.
- GeneDx Holdings Corp. interest income (expense), net for fiscal 2022 was -$666.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$597.00K 10-Q · filed 2024-04-29 | -$1.57M derived: sum of 2 quarters · filed 2024-04-29 | -$522.00K derived: sum of 3 quarters · filed 2024-04-29 | $552.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2023-12-31 | -$978.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $75.00K derived: sum of 2 quarters · filed 2024-02-23 | $1.15M derived: sum of 3 quarters · filed 2024-02-23 | $1.11M 10-K · filed 2024-02-23 |
| 2023-09-30 | $1.05M 10-Q · filed 2023-11-03 | $2.13M derived: sum of 2 quarters · filed 2024-02-23 | $2.09M 10-Q · filed 2023-11-03 | $2.42M derived: sum of 4 quarters · filed 2024-04-29 |
| 2023-06-30 | $1.07M derived: 10-K 12 month − 3 quarters · filed 2024-02-23 | $1.04M derived: sum of 2 quarters · filed 2024-04-29 | $1.37M derived: sum of 3 quarters · filed 2024-04-29 | $1.56M derived: sum of 4 quarters · filed 2024-04-29 |
| 2023-03-31 | -$35.00K 10-Q · filed 2024-04-29 | $298.00K derived: sum of 2 quarters · filed 2024-04-29 | $488.00K derived: sum of 3 quarters · filed 2024-04-29 | |
| 2022-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $523.00K derived: sum of 2 quarters · filed 2024-02-23 | -$666.00K 10-K · filed 2024-02-23 | |
| 2022-09-30 | $190.00K 10-Q · filed 2023-11-03 | -$999.00K 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |